Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ABBVIE INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 138.50 USD | +0.30% | +0.02% | -14.30% | |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
Financials (USD)
| Sales 2023 * | 53.90 B | Sales 2024 * | 53.27 B | Capitalization | 244 B |
|---|---|---|---|---|---|
| Net income 2023 * | 8,765 M | Net income 2024 * | 10.83 B | EV / Sales 2023 * | 5,37x |
| Net Debt 2023 * | 45.52 B | Net Debt 2024 * | 38.88 B | EV / Sales 2024 * | 5,31x |
| P/E ratio 2023 * | 26,3x | P/E ratio 2024 * | 21,2x | Employees | 50,000 |
| Yield 2023 * | 4,32% | Yield 2024 * | 4,50% | Free-Float | 96.74% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.55% | ||
| 1 week | +0.14% | ||
| Current month | -1.78% | ||
| 1 month | -2.27% | ||
| 3 months | -6.04% | ||
| 6 months | +1.63% | ||
| Current year | -14.19% |
1 week
137.65
140.08
1 month
135.85145.71
Current year
130.96168.11
1 year
130.96168.11
3 years
101.55175.91
5 years
62.55175.91
10 years
45.45175.91
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 69 | 2012 |
Scott Reents
DFI | Director of Finance/CFO | 56 | 2012 |
Robert Michael
PSD | President | 52 | 2011 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 62 | 2012 |
Edward J. Rapp
BRD | Director/Board Member | 65 | 2012 |
| Director/Board Member | 69 | 2012 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 8.73% | 3,593 M€ | -6.18% | ||
| 7.12% | 6 M€ | -9.20% | - | |
| 6.86% | 18 M€ | -10.48% | - | |
| 6.85% | 26 M€ | +9.30% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-11-29 | 138.50 | +0.30% | 3 987 938 |
| 23-11-28 | 138.08 | -0.73% | 5,347,231 |
| 23-11-27 | 139.09 | +0.30% | 5,529,373 |
| 23-11-24 | 138.67 | +0.14% | 1,636,535 |
| 23-11-22 | 138.47 | -0.19% | 3,428,670 |
Delayed Quote Nyse, November 29, 2023 at 12:36 pm EST
More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (78.7%), Germany (2.3%), Canada (2%), Japan (1.6%), China (1.6%), France (1.4%), Australia (0.9%), Spain (0.9%), the United Kingdom (0.8%), Italy (0.8%), Brazil (0.7%) and other (8.3%).
Sector
Pharmaceuticals
Calendar
2024-01-11
- U.S. Currency
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
138.08USD
Average target price
167.21USD
Spread / Average Target
+21.09%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -14.19% | 244 B $ | |
| +61.82% | 532 B $ | |
| +46.99% | 452 B $ | |
| -14.09% | 365 B $ | |
| -9.29% | 254 B $ | |
| -18.62% | 216 B $ | |
| +1.50% | 200 B $ | |
| -10.57% | 195 B $ | |
| -41.38% | 168 B $ | |
| -5.53% | 118 B $ |